New Data on Ropeginterferon Alfa-2b to Be Featured at EHA2022

Presentations to illustrate long-term results from the PROUD/CONTINUATION studies as well as new insights on ropeginterferon alfa-2b in polycythemia vera (PV) patients in JapanTAIPEI--(BUSINESS WIRE)--PharmaEssentia Corporation (TPEx:6446), a global biopharmaceutical innovator based in Taiwan leveraging deep experti...

Related Keywords

Taiwan ,Japan ,Yamanashi ,Shizuoka ,United States ,China ,Taipei ,T Ai Pei ,Austria ,Vienna ,Wien ,South Korea ,Japanese ,American ,Taiwanese ,Keita Kirito ,Heinz Gisslinger ,Albert Qin ,European Hematology Association Hybrid Congress ,Pharmaessentia Corporation Tpex ,University Of Yamanashi ,European Medicines Agency ,Pharmaessentia Corporation ,University Vienna ,European Hematology Association ,Hybrid Congress ,Chief Medical Officer ,Achieves Patient Specific Treatment Goals ,Polycythemia Vera ,Final Results ,Medical University Vienna ,Single Arm Study Investigating ,Japanese Patients ,Essentia Corporation ,Fibrotic Progression ,Essential Thrombocythemia ,Literature Review ,Blood Cancer Journal ,